Merli Mauro, Moscatelli Marco, Mariotti Giorgia, Pagliaro Umberto, Raffaelli Eugenia, Nieri Michele
Eur J Oral Implantol. 2015 Autumn;8(3):271-81.
The objective of this parallel randomised controlled trial is to compare two bone substitutes and collagen membranes in a one-stage procedure for horizontal bone augmentation: anorganic bovine bone (Bio-Oss) and collagen porcine membranes (Bio-Gide) (BB group) versus a synthetic resorbable bone graft substitute made of pure β-tricalcium phosphate (Ceros TCP) and porcine pericardium collagen membranes (Jason) (CJ group).
Patients in need of implant treatment having at least one site with horizontal osseous defects at a private clinic in Rimini (Italy) were included in this study. Patients were randomised to receive either the BB or CJ treatment. Randomisation was computer-generated with allocation concealment by opaque sequentially numbered sealed envelopes. Patients and the outcome assessor were blinded to group assignment. The main outcome measures were implant failure, complications, clinical bone gain at augmented sites, and complete filling of the bone defect. Secondary outcome measures were chair-time, postoperative pain and peri-implant marginal bone level changes.
Twenty-five patients with 32 implants were allocated to the BB group and 25 patients with 29 implants to the CJ group. All 50 randomised patients received the treatment as allocated and there were no dropouts up to 6-months post-loading (12 months post-surgery). There were no failures and there were three complications in the BB group and three complications in the CJ group (relative risk: 1.00, 95% CI from 0.22 to 4.49, P = 1.00). The estimated difference between treatments in the vertical defect bone gain was -0.15 mm (95% CI from -0.65 to 0.35, P = 0.5504) favouring the BB group, and the estimated difference between treatments in the horizontal defect bone gain was -0.27 mm (95%CI from -0.73 to 0.19, P = 0.3851) favouring the BB group. There was no difference in the complete filling of the defect (relative risk: 0.88, 95%CI from 0.58 to 1.34, P = 0.7688). No significant differences were detected for chair-time (P = 0.3524), for VAS pain immediately after surgery (P = 0.5644), VAS pain after 1 week (P = 0.5074) and VAS pain after 2 weeks (P = 0.6950). A slight difference (0.24 mm, 95%CI from 0.0004 to 0.47, P = 0.0464) was detected in radiographic peri-implant bone loss favouring the CJ group.
No significant differences, except for radiographic bone loss, were observed in this randomised controlled trial comparing anorganic bovine bone with collagen porcine membranes versus synthetic resorbable bone made of pure β-tricalcium phosphate with pericardium collagen membranes for horizontal augmentation.
本平行随机对照试验的目的是在一期水平骨增量手术中比较两种骨替代物和胶原膜:无机牛骨(Bio-Oss)和猪胶原膜(Bio-Gide)(BB组)与由纯β-磷酸三钙制成的合成可吸收骨移植替代物(Ceros TCP)和猪心包胶原膜(Jason)(CJ组)。
本研究纳入了意大利里米尼一家私人诊所中需要进行种植治疗且至少有一个水平骨缺损部位的患者。患者被随机分配接受BB或CJ治疗。随机分组由计算机生成,通过不透明的顺序编号密封信封进行分配隐藏。患者和结果评估者对分组情况不知情。主要结局指标为种植体失败、并发症、骨增量部位的临床骨增量以及骨缺损的完全填充。次要结局指标为治疗时间、术后疼痛和种植体周围边缘骨水平变化。
25例患者的32颗种植体被分配至BB组,25例患者的29颗种植体被分配至CJ组。所有50例随机分组的患者均按分配接受了治疗,直至加载后6个月(手术后12个月)无脱落病例。两组均无种植体失败,BB组有3例并发症,CJ组有3例并发症(相对风险:1.00,95%CI为0.22至4.49,P = 1.00)。垂直骨缺损处治疗间的估计差异为-0.15 mm(95%CI为-0.65至0.35,P = 0.5504),倾向于BB组;水平骨缺损处治疗间的估计差异为-0.27 mm(95%CI为-0.73至0.19,P = 0.3851),倾向于BB组。骨缺损的完全填充情况无差异(相对风险:0.88,95%CI为0.58至1.34,P = 0.7688)。治疗时间(P = 0.3524)、术后即刻VAS疼痛(P = 0.5644)、术后1周VAS疼痛(P = 0.5074)和术后2周VAS疼痛(P = 0.6950)均未检测到显著差异。在种植体周围影像学骨吸收方面检测到轻微差异(0.24 mm,95%CI为0.0004至0.47,P = 0.0464),倾向于CJ组。
在本随机对照试验中,比较无机牛骨与猪胶原膜和由纯β-磷酸三钙与心包胶原膜制成的合成可吸收骨用于水平骨增量时,除影像学骨吸收外未观察到显著差异。